Sign in Subscribe
Cancer

Imagion Biosystems and Wayne State University Collaborate on Quantum Imaging Technology

Strategic Insights

— 1 min read

Imagion Biosystems has entered into a collaborative service agreement with industry-leading MRI experts at the Wayne State University School of Medicine to develop quantum imaging technology for early cancer detection. This collaboration bolsters the existing agreement Imagion has with Siemens Healthineers, the world's leading manufacturer of MRI equipment. The key objectives of the collaboration include determining the lowest concentration of Imagion's MagSense imaging agent needed for detection, establishing optimized MRI sequences and protocols, and collaborating on the transfer of these protocols to clinical sites for use in the planned MagSense HER2 Phase 2 study.

Key Takeaways:

  • Imagion Biosystems has entered into a collaborative service agreement with Wayne State University School of Medicine to develop quantum imaging technology for early cancer detection.
  • The collaboration aims to determine the lowest concentration of Imagion's MagSense imaging agent needed for detection and establish optimized MRI sequences and protocols.
  • Quantitative imaging techniques will be employed to yield AI-compatible image data and improve diagnostic accuracy.
  • The collaboration will focus on using Siemens' top-of-the-line scanners to develop optimized sequences that can be used in the upcoming MagSense HER2 Phase 2 study.
  • Imagion's MagSense imaging agents have the potential to enable not only automatic detection and differentiation of normal vs. cancerous tissue but also enable improved staging, tracking, and treatment monitoring.
  • The collaboration will lay the foundation for future automated analysis of MagSense images using AI.
  • Quantitative MRI pioneer Dr. Mark Haacke will lead the collaboration, bringing his expertise in quantitative MRI and the development of high-resolution imaging to identify new biomarkers.

Statistics:

  • Imagion Biosystems has entered into a collaborative service agreement with Wayne State University School of Medicine.
  • The collaboration aims to determine the lowest concentration of Imagion's MagSense imaging agent needed for detection (undisclosed).
  • Quantitative imaging sequences will be employed to yield AI-compatible image data, improving diagnostic accuracy for cancer detection.
  • The collaboration will focus on using Siemens' top-of-the-line scanners to develop optimized sequences for the upcoming MagSense HER2 Phase 2 study.
  • Imagion's MagSense imaging agents have the potential to enable not only automatic detection and differentiation of normal vs. cancerous tissue but also enable improved staging, tracking, and treatment monitoring.

Sources:

  • Imagion Biosystems Limited news release.
  • Wayne State University School of Medicine.
  • Siemens Healthineers.

Read more